The Effect of Bitter, Umami and Sweet Tastants on Food Intake

NCT01956838 | Completed

• 1 other identifier: NL44428.068.13/METC 13-2-025
• Study Type: interventional
• Target: 15
• Locations: 1 country
• Sites: 1

Brief Summary

Rationale: The appearance of tastants in the small intestine can result in the activation of a negative feedback mechanism from different parts of the intestine to the stomach, the small intestine and to the central nervous system. These processes inhibit food processing, appetite sensations and food intake, and furthermore they increase feelings of satiety and satiation. We will investigate the effects of intraduodenal infusion of quinine 75mg (bitter), rebaudioside A 540mg (sweet), monosodium glutamate 2g (umami), a combination of these tastants (quinine, rebaudioside A, monosodium glutamate) and placebo (5 test days in total) on ad libitum food intake, satiation and in vivo release of the gut satiety peptides CCK and GLP-1. Study design: To assess the effect of intraduodenal infusion of single ingredients and a combination of tastants (bitter, umami and sweet) on ad libitum food intake. Secondary Objective(s):

1. 1.To investigate the effect of intraduodenal delivery of a combination of tastants on satiation.
2. 2.To assess the effect of intraduodenal delivery of a combination of tastants on gastrointestinal hormone release.
3. 3.To assess the effects of the tastants quinine, rebaudioside A and monosodium glutamate on the parameters as mentioned under the primary objective, and under secondary objectives 1 and 2.
4. 4.To compare the effects, as mentioned under the primary objective, and under secondary objectives 1 and 2, of the combination of tastants to those of the three single tastants quinine, rebaudioside A and monosodium glutamate.

Conditions

Obesity

Keywords

food intake; tastants; obesity

Outcome Measures

Primary Outcomes (1)

• Ad libitum meal intake

  Difference in ad libitum meal intake (as measured during ad libitum pasta meal). At end of the testday

  5 weeks

Secondary Outcomes (2)

• Satiation

  5 weeks

• Gut hormones

  5 weeks

Study Arms (5)

Umami

EXPERIMENTAL

intraduodenal infusion of umami

Dietary Supplement: umami

sweet

EXPERIMENTAL

intraduodenal infusion of sweet tastant

Dietary Supplement: sweet

bitter

EXPERIMENTAL

intraduodenal infusion of bitter tastant

Dietary Supplement: bitter

combination

EXPERIMENTAL

intraduodenal infusion of a combination of tastants (umami, bitter and sweet)

Dietary Supplement: umami; Dietary Supplement: bitter; Dietary Supplement: sweet

placebo

PLACEBO COMPARATOR

intraduodenal infusion of placebo (tap water)

Interventions

umami DIETARY_SUPPLEMENT

intraduodenal infusion of umami tastant

Umami; combination

bitter DIETARY_SUPPLEMENT

intraduodenal infusion of bitter tastant

bitter; combination

sweet DIETARY_SUPPLEMENT

intraduodenal infusion of sweet tastant

combination; sweet

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Based on medical history and previous examination, no gastrointestinal complaints can be defined.
• Age between 18 and 65 years. This study will include healthy adult subjects (male and female). Women must be taking contraceptives.
• BMI between 18 and 25 kg/m2)
• Weight stable over at least the last 6 months

You may not qualify if:

• History of severe cardiovascular, respiratory, urogenital, gastrointestinal/ hepatic, hematological/immunologic, HEENT (head, ears, eyes, nose, throat), dermatological/connective tissue, musculoskeletal, metabolic/nutritional, endocrine, neurological/psychiatric diseases, allergy, major surgery and/or laboratory assessments which might limit participation in or completion of the study protocol. The severity of the disease (major interference with the execution of the experiment or potential influence on the study outcomes) will be decided by the principal investigator.
• Use of medication, including vitamin supplementation, except oral contraceptives, within 14 days prior to testing
• Administration of investigational drugs or participation in any scientific intervention study which may interfere with this study (to be decided by the principle investigator), in the 180 days prior to the study
• Major abdominal surgery interfering with gastrointestinal function (uncomplicated appendectomy, cholecystectomy and hysterectomy allowed, and other surgery upon judgement of the principle investigator)
• Dieting (medically prescribed, vegetarian, diabetic, macrobiological, biological dynamic)
• Pregnancy, lactation
• Excessive alcohol consumption (\>20 alcoholic consumptions per week)
• Smoking
• Blood donation within 3 months before the study period
• Self-admitted HIV-positive state
• Weight \<60kg
• Non-tasters of sweet, bitter or umami
• Evidence of MSG-hypersensitivity or Chinese restaurant syndrome

Sponsors & Collaborators

• Maastricht University Medical Center: lead

Study Sites (1)

Maastricht University Medical Center

Maastricht, Maastricht, Netherlands

Location

Related Publications (1)

• van Avesaat M, Troost FJ, Ripken D, Peters J, Hendriks HF, Masclee AA. Intraduodenal infusion of a combination of tastants decreases food intake in humans. Am J Clin Nutr. 2015 Oct;102(4):729-35. doi: 10.3945/ajcn.115.113266. Epub 2015 Aug 19.

  PMID: 26289437 DERIVED

MeSH Terms

Conditions

Obesity

Interventions

Candy

Condition Hierarchy (Ancestors)

Overweight; Overnutrition; Nutrition Disorders; Nutritional and Metabolic Diseases; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Food; Diet, Food, and Nutrition; Physiological Phenomena; Food and Beverages

Study Officials

• Prof Masclee, MD,PhD

  Maastricht University Medical Center

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Purpose: BASIC SCIENCE
• Intervention Model: CROSSOVER
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 17, 2013
• First Posted: October 8, 2013
• Study Start: September 1, 2013
• Primary Completion: August 1, 2014
• Study Completion: August 1, 2014
• Last Updated: October 15, 2014

Record last verified: 2014-10

Locations

NL (1)